Cargando…

Hepatitis C virus prevention and care for drug injectors: the French approach

After France removed hepatitis C treatment reimbursement restrictions on 25 May 2016, an expert report presented recommendations, which focused on vulnerable groups including people who inject drugs (PWID). This commentary presents the key points of the chapter with a particular focus on policy. Tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delile, Jean-Michel, de Ledinghen, Victor, Jauffret-Roustide, Marie, Roux, Perrine, Reiller, Brigitte, Foucher, Juliette, Dhumeaux, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Debate
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987624/ https://www.ncbi.nlm.nih.gov/pubmed/30288330 http://dx.doi.org/10.1186/s41124-018-0033-8

Ejemplares similares

Limited access to HIV prevention in French prisons (ANRS PRI(2)DE): implications for public health and drug policy
por: Michel, Laurent, et al.
Publicado: (2011)

A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study
por: Werb, Daniel, et al.
Publicado: (2016)

The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
por: Schatz, Eberhard, et al.
Publicado: (2016)

Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts
por: Benjamin, Laure, et al.
Publicado: (2014)

Securizing data linkage in french public statistics
por: Guesdon, Maxence, et al.
Publicado: (2016)

Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol
por: Auriacombe, Marc, et al.
Publicado: (2019)

The French Covid-19 vaccination policy did not solve vaccination inequities: a nationwide study on 64.5 million people
por: Débarre, Florence, et al.
Publicado: (2022)

Syringe access for the prevention of blood borne infections among injection drug users
por: Stancliff, Sharon, et al.
Publicado: (2003)

Migration experiences, life conditions, and drug use practices of Russian-speaking drug users who live in Paris: a mixed-method analysis from the ANRS-Coquelicot study
por: Tibi-Lévy, Yaël, et al.
Publicado: (2020)

Hepatic Steatosis, Carbohydrate Intake, and Food Quotient in Patients with NAFLD
por: Gonzalez, Concepcion, et al.
Publicado: (2013)

Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
por: Dal-Ré, Rafael, et al.
Publicado: (2018)

Link Between Perception of Treatment Need and Craving Reports in Addiction
por: Lambert, Laura, et al.
Publicado: (2022)

The polysemy of psychotropic drugs: continuity and overlap between neuroenhancement, treatment, prevention, pain relief, and pleasure-seeking in a clinical setting
por: Sakakibara, Eisuke
Publicado: (2020)

Lessons from obesity prevention for the prevention of mental disorders: the primordial prevention approach
por: Hayward, Joshua, et al.
Publicado: (2014)

Roundtable discussion: how the World Hepatitis Summit 2015 strengthened stakeholders’ efforts to combat viral hepatitis
por: Gore, Charles, et al.
Publicado: (2016)

On fractional order models for Hepatitis C
por: Ahmed, E, et al.
Publicado: (2010)

On multi-strain model for Hepatitis C
por: Ahmed, E, et al.
Publicado: (2011)

New algorithm for OHSS prevention
por: Papanikolaou, Evangelos G, et al.
Publicado: (2011)

Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access
por: Maponga, Tongai G., et al.
Publicado: (2017)

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
por: Mencher, Simon K, et al.
Publicado: (2005)

Pathways to ensure universal and affordable access to hepatitis C treatment
por: Douglass, Caitlin H., et al.
Publicado: (2018)

Prevention among immigrants: the example of Germany
por: Spallek, Jacob, et al.
Publicado: (2010)

Estimating prevalence from dried blood spots without using biological cut-offs: application of a novel approach to hepatitis C virus in drug users in France (ANRS-Coquelicot survey)
por: Léon, L., et al.
Publicado: (2019)

Why all blood donations should be tested for hepatitis E virus (HEV)
por: Denner, Joachim, et al.
Publicado: (2019)

Human endogenous retroviruses and cancer prevention: evidence and prospects
por: Cegolon, Luca, et al.
Publicado: (2013)

Human genome editing: how to prevent rogue actors
por: Townsend, Beverley A.
Publicado: (2020)

A public health approach to understanding and preventing violent radicalization
por: Bhui, Kamaldeep S, et al.
Publicado: (2012)

Making the economic case for prevention – a view from Wales
por: Hale, Janine, et al.
Publicado: (2012)

Towards a comprehensive global approach to prevention and control of NCDs
por: McKee, Martin, et al.
Publicado: (2014)

The physician's unique role in preventing violence: a neglected opportunity?
por: Umhau, John C, et al.
Publicado: (2012)

Requirements for more effective prevention of work-related musculoskeletal disorders
por: Macdonald, Wendy, et al.
Publicado: (2015)

Effectively engaging stakeholders and the public in developing violence prevention messages
por: Boyko, Jennifer A., et al.
Publicado: (2017)

Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues
por: Nugent, Allison C., et al.
Publicado: (2019)

Grounding implementation science in health equity for cancer prevention and control
por: Adsul, Prajakta, et al.
Publicado: (2022)

What else can we do to prevent diabetic retinopathy?
por: Simó, Rafael, et al.
Publicado: (2023)

Hepatitis B virus infected physicians and disclosure of transmission risks to patients: A critical analysis
por: Barrigar, Diana L, et al.
Publicado: (2001)

The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
por: Mesquita, Fabio, et al.
Publicado: (2016)

Is there a role of synovial biopsy in drug development?
por: Filkova, Maria, et al.
Publicado: (2016)

Heterogeneity of Alzheimer’s disease: consequence for drug trials?
por: Devi, Gayatri, et al.
Publicado: (2018)

Ethics framework for treatment use of investigational drugs
por: Borysowski, Jan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h143tbbj0fl3mvu024ob4ojng8